USPTO serial 98217245
VECTURA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 12, 2026
- Examiner
- PERRY, KIMBERLY B
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with VECTURA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Molly B. Markley
Molly B. Markley YOUNG, BASILE, HANLON & MACFARLANE P.C.3001 WEST BIG BEAVER ROADSUITE 624TROY, MI 48084Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary preparations for the treatment of diseases or conditions of the respiratory system; pharmaceutical and veterinary preparations for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; pharmaceutical and veterinary preparations for the alleviation or prevention of pain or inflammation; inhalers filled with powders for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; pharmaceutical preparations, namely, powders for asthma inhalers; pharmaceutical preparations, namely, powders for transdermal injection for the alleviation or prevention of pain, for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for oral ingestion for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for topical administration for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; medicaments for inhalation therapy; pharmaceutical preparations, namely, pulmonary delivery compositions for use in facilitating the inhalation of pharmaceuticals, namely, drug delivery agents consisting of compounds that facilitate delivery by inhalation of a wide range of pharmaceuticals; medicaments for the treatment of erectile dysfunction; medicaments for the treatment of chronic obstructive pulmonary disease; medicaments for the treatment of premature ejaculation; medicaments for the treatment of cystic fibrosis; medicaments for the treatment of female sexual dysfunction; medicaments for the treatment of migraines; medicaments for the treatment of asthma; all of the above goods not for use in the dental field | ACTIVE | — |
| 010 | Surgical, medical, and veterinary apparatus, instruments and parts and fittings therefor, namely, drug delivery devices and parts and fittings therefor, namely, drug delivery systems being nebulizers for medical purposes; inhalers sold empty for medical or therapeutic purposes and parts and fittings therefor; active dry powder inhalers sold empty for medical or therapeutic purposes and parts and fittings therefor; passive dry powder inhalers sold empty for medical or therapeutic purposes and parts and fittings therefor; nebulisers for inhalation therapy, namely, respiration therapy, and parts and fittings therefor; inhaler devices sold empty for medical or therapeutic purposes and parts and fittings therefor; all of the above goods not for use in the dental field | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals; Consulting services in the field of pharmaceutical formulation, development of medical applications for drugs and pharmaceutical formulations, drug design, drug formulation, pharmaceutical formulation, and development of pharmaceutical formulations | ACTIVE | — |
| 042 | Scientific research and technological services, namely, research, design, analysis, and testing, in the field of pharmaceuticals and drug delivery systems, and drug delivery systems and devices; Scientific research and technological services, namely, research in the field of medicine; industrial analysis and research services in the fields of drug delivery systems and devices; research services in the fields of medicine; pharmaceutical research services; pharmaceutical products development services; device and product safety testing services; | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Vectura Limited
- Other trademarks owned by Vectura Limited
- Other trademarks owned by Vectura Limited
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named VECTURA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 12, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 12, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 24, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 24, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 18, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 27, 2026 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Feb 23, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 19, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 19, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 19, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 22, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 22, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 22, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 22, 2026 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jan 16, 2026 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Jan 8, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 8, 2026 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Apr 21, 2025 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Sep 12, 2024 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Sep 9, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 6, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 6, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 6, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 10, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 10, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 10, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 29, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 16, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 13, 2023 | NWAP | NEW APPLICATION ENTERED | — |